E Fund Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

E Fund Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,377	Closed	-$362K	–	342
2023 Q1	$362K	Sell	3,377 -459	-12%	-$52.8K	0.03%	200
2022 Q4	$422K	Sell	3,836 -2,696	-41%	-$175K	0.04%	171
2022 Q3	$385K	Buy	+6,532	New	+$299K	0.04%	190

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

E Fund Management's RXDX Position: Q2 2023 in Review

E Fund Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,377 shares — an estimated $362K sold.

E Fund Management first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $422K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

E Fund Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
E Fund Management sold 3,377 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $362K.
E Fund Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
E Fund Management's Prometheus Biosciences, Inc. Common Stock position peaked at $422K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.